These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29272262)

  • 21. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
    Fenger-Eriksen C; Münster AM; Grove EL
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):651-9. PubMed ID: 24716468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review.
    Maniscalco P; Caforio M; Imberti D; Porcellini G; Benedetti R
    Clin Appl Thromb Hemost; 2015 Mar; 21(2):115-9. PubMed ID: 25125051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
    King DA; Pow RE; Dickison DM; Vale PR
    Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coagulation assays in a case of apixaban overdose.
    Guadarrama DS; DeMarinis SM; Sweeney JD
    Blood Coagul Fibrinolysis; 2018 Mar; 29(2):231-235. PubMed ID: 29369080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
    Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
    Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.
    Beyer-Westendorf J; Lensing AW; Arya R; Bounameaux H; Cohen AT; Wells PS; Middeldorp S; Verhamme P; Hughes R; Kucher N; Pap AF; Trajanovic M; Prins MH; Prandoni P; Weitz JI
    Thromb Res; 2017 Jan; 149():29-37. PubMed ID: 27886530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Proper use of apixaban: an outline for clinical practice].
    Albaladejo P; Deplanque D; Fossati F; Mahagne MH; Mismetti P; Nguyen P; Roy P; Touze E; Mourad JJ
    J Mal Vasc; 2014 Dec; 39(6):409-25. PubMed ID: 25451020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
    Pollack CV
    Circulation; 2016 Jan; 133(2):e18-9. PubMed ID: 27028439
    [No Abstract]   [Full Text] [Related]  

  • 30. Utilization of thromboelastography and a low molecular weight heparin anti-Xa assay for guidance in apixaban reversal: A case report.
    Gilbert BW; Adams TR; Reynolds TR; Moran DA; Philip GJ
    Am J Emerg Med; 2019 Oct; 37(10):1991.e1-1991.e3. PubMed ID: 31375354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New oral anticoagulants in patients with atrial fibrillation in a urban health center].
    Rodríguez Pérez L; Capilla Lozano F; Gallego Fuentes R; Buitrago F
    Med Clin (Barc); 2016 Mar; 146(6):280-1. PubMed ID: 26343157
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of factor Xa inhibitors in venous thromboembolism treatment.
    Cabral KP; Ansell JE
    Vasc Health Risk Manag; 2015; 11():117-23. PubMed ID: 25673997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
    Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement.
    Seeger J; Gonska B; Rodewald C; Rottbauer W; Wöhrle J
    JACC Cardiovasc Interv; 2017 Jan; 10(1):66-74. PubMed ID: 27916486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology and laboratory testing of the oral Xa inhibitors.
    Samama MM; Meddahi S; Samama CM
    Clin Lab Med; 2014 Sep; 34(3):503-17. PubMed ID: 25168939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Not Available].
    Själander S; Själander A
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
    [No Abstract]   [Full Text] [Related]  

  • 37. ACP Journal Club: review: in renal impairment, apixaban reduces, or does not increase, bleeding compared with other anticoagulants.
    Ribic CM; Clase CM
    Ann Intern Med; 2015 Apr; 162(8):JC3. PubMed ID: 25894048
    [No Abstract]   [Full Text] [Related]  

  • 38. Major bleeding with apixaban in atrial fibrillation: patient characteristics, management, and outcomes.
    Eisho S; Salem NM; Hoffman JL; Koerber JM; Smythe MA
    Hosp Pract (1995); 2018 Oct; 46(4):165-169. PubMed ID: 30058431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
    Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
    J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracraneal hemorrhage during apixaban treatment.
    Sorigue M; Sarrate E; Orna E
    Med Clin (Barc); 2017 Jan; 148(1):47-48. PubMed ID: 27823792
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.